HC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 444.96% from the company’s previous close.

Checkpoint Therapeutics Stock Performance

Shares of CKPT opened at $3.67 on Monday. Checkpoint Therapeutics has a 1 year low of $1.36 and a 1 year high of $4.50. The stock has a market capitalization of $179.21 million, a PE ratio of -1.99 and a beta of 1.34. The stock has a 50-day simple moving average of $3.48 and a 200-day simple moving average of $2.66.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Analysts predict that Checkpoint Therapeutics will post -0.91 EPS for the current year.

Hedge Funds Weigh In On Checkpoint Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Magnus Financial Group LLC boosted its holdings in shares of Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after buying an additional 4,000 shares in the last quarter. Choreo LLC lifted its holdings in shares of Checkpoint Therapeutics by 12.2% in the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares during the last quarter. PVG Asset Management Corp boosted its position in shares of Checkpoint Therapeutics by 9.2% in the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after purchasing an additional 12,676 shares during the period. Virtu Financial LLC purchased a new position in Checkpoint Therapeutics during the 3rd quarter worth approximately $30,000. Finally, XTX Topco Ltd acquired a new position in Checkpoint Therapeutics during the second quarter worth approximately $34,000. 22.00% of the stock is owned by institutional investors and hedge funds.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.